From its base in Valhalla, Tinkeso Therapeutics develops off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for cancers and autoimmune disorders. Formerly known as Akeso Therapeutics, the early-stage biotech combines native and engineered NKT programs, including a non-genome-edited CD7 CAR-iNKT therapy aimed at blood cancers and a native type III NKT approach for acute myeloid leukemia. Its proprietary expansion platform is designed to produce at least 100 doses of CAR-modified iNKT cells from a single donor leukopak.
Autolus TherapeuticsSpun out of University College London in 2014, Autolus Therapeutics develops programmed autologous CAR T-cell therapies for cancer and autoimmune diseases. The company combines T-cell programming with clinical development and a 70,000-square-foot commercial manufacturing facility in Stevenage, UK, and its pipeline includes obe-cel and other investigational therapies. Its long-running collaboration with UCL remains central to moving programs from the laboratory into clinical studies.GAITHERSBURG, MD
Iovance Biotherapeutics, IncIovance Biotherapeutics develops and manufactures personalized tumor-infiltrating lymphocyte (TIL) cell therapies for people with cancer. Its 136,000-square-foot Iovance Cell Therapy Center in Philadelphia makes TIL therapy using proprietary processes, including a 22-day Gen 2 process; the company also markets Amtagvi and Proleukin.PHILADELPHIA, PA
Kite PharmaKite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.FREDERICK, MD
AdaptimmuneAdaptimmune develops engineered T-cell receptor (TCR) therapies designed to direct the immune system against cancer, with a particular focus on solid tumors. Based in Oxfordshire, the company has built its platform over more than 15 years to identify cancer targets, enhance T-cell receptor affinity and screen candidates for potential off-target binding.541714PHILADELPHIA, PA